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Background
•
•

Results

Goblet Cell tumors (GCTs) of the appendix are a rare,
distinct, and under studied malignancy
Since 2019 the preferred World Health Organization (WHO)
terminology is Goblet Cell Adenocarcinoma (GCA), but
previously many terms have been used to describe these
tumors including Goblet Cell Carcinoid and Adenocarcinoma
ex goblet cell carcinoid as these tumors have a histological
appearance that blends neuroendocrine and
adenocarcinoma features

•

Historically goblet cell tumors have been considered one of
the more aggressive subtypes of appendiceal cancer, but
limited data exists and is mostly in the form of case reports

•

Here we present the retrospective analysis of a large single
institution cohort.

•

366 patients with GCTs were identified from 1986 to 2022

•

132 (36%) patients were seen during the last five years, with an average of 26 patients per year

•

Median follow up time was 54 months, while median age at diagnosis was 57 years

•

Tumor grade data was available for 294 patients. 95% of the patients had high grade tumors (moderately,
moderately to poorly and poorly-differentiated) (n= 278), and 5% had low grade tumors (well and well to
moderately-differentiated (n=16)

•

The median overall survival was 85 months, and significantly different between the two groups, 118 months
for the GCA group and 57 months for the GCA with SRA (HR, 1.7; 95% CI, 1.2 to 2.4; p = 0.003)

•

The internal database of MDACC was queried for LN status
of Mucinous adenocarcinoma (MA) (n=242) and SRA
(n=104) for comparison purposes, rate of LN positivity was
13% in MA and 76% in SRA

•

By multivariate analysis, both LN status and SRA
component were independent predictors of overall survival

•

107 patients had gene mutation analysis tested, TP53,
SMAD4, GNAS and KRAS were the most commonly
mutated with 13%, 9%, 4%, and 3% respectively

Patients and Methods
•

The internal database of the University of Texas MD
Anderson Cancer Center (MDACC) was queried to identify all
patients diagnosed with goblet cell appendiceal tumor

•

Patients were classified to two different histopathological
groups, GCA (n=220) and GCA with signet ring
adenocarcinoma (SRA) (n=146)
Clinical, histopathological, and molecular data were
extracted from the database in semi-automated fashion

•
•

Survival analysis were performed using Kaplan Meier
methodology

Fig 4. Rate of LN affection in different histopathological subtypes of Appendiceal
Adenocarcinoma among MDACC patients
Fig 2. KM plots for patients with GCA vs GCA with SRA

•

Lymph node (LN) status was known for 168 patients, rate of LN involvement was 53% (n=89) and significantly
different between the two groups with 41% (n=39) for GCA and 68% (n=50) for GCA with SRA (p= <0.0006)

•

The median overall survival was significantly different between the LN positive and negative patients, 84.5
months for the LN positive group and 50.6 months for the LN negative group (HR, 2; 95% CI, 1.2 to 3.2; p =
0.004)

Fig 5. Most commonly mutated genes in the patients and rate of each one

Conclusions
•

This study highlights the heterogenicity of GCTs of the
appendix and the importance of the histopathological
classification in this distinct entity. GCT are much more
likely to spread to LN and have a distinct somatic mutation
profile relative to MA
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